Loading song details...
AGDD 2024 D2S05 1 Totality Of Evidence Including Physiologically Based Pharmacokinetic Modeling
No description available.
MP3 Download
Video Download
Related Songs
11:54
AGDD 2024 D2S05 1 Totality Of Evidence Including Physiologically Based Pharmacokinetic Modeling
11:30
AGDD 2024 D2S05 2 Totality Of Evidence Including PBPK Modeling To Support BE Assessment
32:15
GDF 2024 D2S05 Q A Discussion Panel 1
16:14
AGDD 2024 D1S02 IVRT Methods For In Situ Depot Forming Long Acting Injectable Products
14:44
AGDD 2025 D2S05 Workshop Closing Remarks
29:19
AGDD 2024 D2S07 The Journey Of First Approvals Complex Generic Long Acting Injectable Products
17:12
AGDD 2024 D1S07 Enhanced Understanding Of Structure Performance Relationship Using Modeling
22:53
AGDD 2024 D1S10 Orally Inhaled Drug Product PSGs General Considerations Using The Alternative
15:29
AGDD 2024 D1S11 Orally Inhaled Drug Product PSGs Considerations For Using Modeling And Sim
18:42
AGDD 2024 D1S08 Approaches For Evaluation Of Formulation Differences On Performance Topical
9:20
AGDD 2024 D2S10 1 Analysis Of First Cycle BE Adequacy And Major Deficiencies Encountered
21:06
AGDD 2024 D2S09 Guidance For Industry Content And Format Of Composition Statement
7:07
AGDD 2024 D2S14 Closing Remarks
15:26
AGDD 2024 D2S12 Model Integrated Evidence MIE Industry Meeting Pilot Program For Generic
17:29
AGDD 2024 D1S01 Keynote Address
22:47
AGDD 2024 D1S14 Drug Device Combination Products A New Methodology For Evaluation
21:59
AGDD 2024 D2S02 Quality Considerations For First Generic Oral Liquids
22:07
AGDD 2024 D2S06 Emerging Generic Oligonucleotides Challenges And Progress
27:38
AGDD 2024 D2S04 Q A Discussion Panel 1
5:24